Skip to main content

Table 3 Base case results of the model

From: Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance

Model outcomes

Cabazitaxel

ASTI

Cost ($)

 Costs in PFS

94,672.44

43,831.50

 Costs in PD

10,497.26

11,851.17

 Total costs

105,169.70

55,682.67

 Incremental costs

49,487.03

–

Effectiveness (QALYs)

 QALYs in PFS

0.40

0.19

 QALYs in PD

0.17

0.22

 Total effectiveness

0.57

0.41

 Incremental effectiveness

0.16

–

ICER ($/QALY)

309,293.94

  1. ASTI androgen-signaling-targeted inhibitor, PFS progression-free survival, OS overall survival, QALYs quality-adjusted life years, IECR incremental cost-effectiveness ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us